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CLINICAL RESEARCH ARTICLE
Pharmacological-assisted Psychotherapy for Post-Traumatic Stress Disorder: a 
systematic review and meta-analysis
Mathew D. Hoskins, Robert Sinnerton, Anna Nakamura, Jack F. G. Underwood, Alan Slater, Catrin Lewis , 
Neil P. Roberts , Jonathan I. Bisson , Matthew Lee and Liam Clarke
Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, Wales, UK
ABSTRACT
Background: Pharmacological-assisted psychotherapies, using conventional and novel drug 
agents, are increasingly being used both in clinical and experimental research settings, 
respectively.
Objective: To determine the efficacy of conventional and novel pharmacological-assisted 
psychotherapies in reducing PTSD symptom severity.
Method: A systematic review and meta-analysis of randomised-controlled trials were under-
taken; 21 studies were included.
Results: MDMA-assisted therapy was found to statistically superior to active and inactive 
placebo-assisted therapy in reduction of PTSD symptoms (standardised mean difference 
−1.09, 95% CI −1.60 to −0.58). There was no evidence of superiority over placebo for any 
other intervention.
Conclusions: MDMA-assisted therapy demonstrated an impressive effect size; however, it is 
difficult to have confidence at this stage in this intervention due to the small numbers of 
participants included, and more research in this area is needed. There was no evidence to 
support the efficacy of any other drug-assisted interventions.
Psicoterapia Asistida Farmacologicamente para el Trastorno de Estres 
Postraumatico: una Revision Sistematica y Metanalisis
Antecedentes: Las psicoterapias asistidas farmacológicamente, que utilizan fármacos con-
vencionales y nuevos, están siendo cada vez más utilizadas tanto en contextos clínicos como 
de investigación experimental, respectivamente.
Objetivos: Determinar la eficacia de las psicoterapias asistidas con fármacos convencionales 
y nuevos para reducir la severidad de los síntomas TEPT.
Método: Se llevó a cabo una revisión sistemática y un metanálisis de estudios controlados 
aleatorizados; se incluyeron 21 estudios.
Resultados: Se encontró que la terapia asistida por MDMA era estadísticamente superior 
a terapia asistida por placebo activo e inactivo en la reducción de los síntomas de TEPT 
(diferencia de medias estandarizada −1.09, IC del 95%: −1.60 a −0.58). No hubo evidencia de 
superioridad sobre placebo para ninguna otra intervención.
Conclusiones: La terapia asistida por MDMA demostró un tamaño de efecto impresio-
nante; sin embargo es difícil tener confianza en esta etapa en esta intervención debido al 
pequeño número de participantes incluidos, y se necesita más investigación en esta área. 







结果: 发现在降低PTSD症状方面, MDMA辅助治疗在统计学上优于阳性对照和安慰剂辅助 
治疗 (标准平均差-1.09, 95%CI −1.60至-0.58) 。没有证据表明任何其他干预措施优于安慰 
剂的证据。
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HIGHLIGHTS 
• We found that MDMA- 
assisted therapy is a novel 
and promising new 
treatment for severe PTSD.  
• Despite demonstrating an 
impressive effect size, more 
research is needed due to 
the small numbers of 
participants included.  
• We did not find evidence 
to recommend any other 
drug-assisted psychological 
intervention. 
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1. Background
Post-traumatic stress disorder is a common, serious 
and debilitating illness, that often runs a chronic 
course (Santiago et al., 2013). Trauma-focused psy-
chological therapies (TFPT) are well established as 
the treatments of choice for PTSD (National 
Collaborating Centre for Mental Health, 2005) and 
often utilise narrative imagery to reprocess traumatic 
memories (Bisson et al., 2007). Manualized, evidence- 
based, trauma-focused psychotherapies include pro-
longed exposure (PE), cognitive processing therapy 
(CPT), cognitive therapy for PTSD (CT-PTSD), and 
eye movement desensitization and reprocessing 
(EMDR).
For exposure-based TFPTs to be effective, people 
with PTSD need to remain emotionally engaged with 
the traumatic memory during exposure (Foa, Hembree, 
& Rothbaum, 2007) to facilitate fear extinction 
(McNally, 2007; Myers & Davis, 2007). For cognitive- 
based TFPTs to be effective, people with PTSD need to 
re-appraise the distorted beliefs that are often attached 
to emotionally distressing memories. Successful TFPT 
can lead to improved inhibition of fear responses and 
improved emotional regulation (Myers & Davis, 2007). 
However, people with PTSD are prone to extremes of 
overwhelming distress and emotional numbing (Foa 
et al., 2007), making it difficult to both tolerate and 
engage with TFPT, within what is called the ‘optimal 
arousal zone’ (Myers & Davis, 2007; Ogden, Minton, & 
Pain, 2006).
Moreover, the quality of the relationship between 
therapist and patient (the therapeutic alliance) is crucial 
to a positive outcome in TFPT (Charuvastra & CLoitre, 
2008); mitigating against this are characteristic feelings 
of social detachment (Charuvastra & CLoitre, 2008; 
Johansen & Krebs, 2009) and hypervigilance in PTSD 
(Santiago et al., 2013). In clinical trials, 67% of patients 
who complete a course of TFPT no longer meet the 
criteria for PTSD (Brady, Green, Russ, Dutra, & 
Westen, 2005). Unfortunately, clinical trials of TFPT 
are associated with high dropout rates (up to 54% has 
been reported) (Schottenbauer, Glass, Arnkoff, 
Tendick, & Gray, 2008), and are ineffective in nearly 
half of patients who are able to tolerate it (Brady et al., 
2005); with higher PTSD severity predicting a poor 
response (Blanchard et al., 2003).
Pharmacological treatments have also been shown 
to reduce PTSD symptom severity, albeit with 
a relatively small effect size (Hoskins et al., in press). 
We have found evidence to support the monotherapy 
use of the selective serotonin reuptake inhibitors 
(SSRIs) paroxetine, fluoxetine, sertraline, the serotonin 
noradrenaline reuptake inhibitor (SNRI) venlafaxine 
and the atypical antipsychotic quetiapine (Hoskins 
et al., in press). We also found evidence for the aug-
mentation of mono pharmacotherapy with the alpha-1 
adrenoceptor antagonist prazosin and the atypical 
antipsychotic risperidone (Hoskins et al., in press).
The overall disappointing results of either psycho-
logical or pharmacological treatment approaches for 
PTSD has led to a small but growing body of literature 
assessing the efficacy of combining pharmacological 
agents with psychotherapies. This can be divided into 
two categories; conventional pharmacological agents, 
such as SSRIs and SNRIs, which are taken daily, along-
side a course of therapy; and unconventional agents, 
such as d-cycloserine (DCS), a partial NMDA agonist, 
and the empathogenic psychedelic 3,4-methylenediox-
ymethamphetamine (MDMA), which are taken imme-
diately prior to a limited number of psychotherapy 
sessions in order to enhance a therapeutic process. 
We will explore the details of these interventions in 
our discussion.
Recent and previous reviews have investigated 
MDMA (Bahji, Forsyth, Groll, & Hawken, 2019) and 
DCS-assisted therapy (Mataix-Cols et al., 2017) in 
PTSD; this review seeks to investigate and compare all 
drug-assisted interventions with a unified methodology, 
as part of a series of two reviews by the authors to 
investigate the evidence base for all pharmacological 
approaches when treating PTSD. Our other review 
focused on pharmacological monotherapy, augmenta-
tion, pharmacotherapy versus pharmacotherapy, and 
pharmacotherapy versus psychotherapy (EJPT ref to be 
inserted).
2. Method
This was a systematic review and meta-analysis 
adhering to the Cochrane Collaboration’s standard 
methodology (Higgins & Green, 2011).
2.1. Participants
All studies where at least 70% of participants diag-
nosed with PTSD according to ICD or DSM criteria 
by means of a structured interview or diagnosis by 
a clinician were eligible. The lower age limit was 
18 years with no restriction on the upper age limit. 
There was no restriction on the basis of gender or of 
comorbidity but PTSD was required to be the pri-
mary diagnosis. The duration of PTSD symptoms was 
required to be at least 3 months. There was no 
restriction on the basis of severity of PTSD symptoms 
or the type of traumatic event. There was no mini-
mum sample size and unpublished studies were eli-
gible. Only studies published in English were eligible.
2.2. Interventions
Any randomised-controlled trial evaluating the efficacy 
of pharmacological-assisted psychotherapy aimed at 
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reducing the symptoms of PTSD in adults, in which the 
comparator of at least one arm was a psychotherapy, 
medication, or psychotherapy plus placebo.
2.3. Outcome measures
The primary outcomes of interest were clinician- 
administered continuous measures of PTSD symptom 
severity such as the Clinician Administered PTSD Scale 
(CAPS). Self-rated PTSD symptom scales were consid-
ered if clinician-administered scales were not reported.
2.4. Search strategy
This review used a common search strategy with the 
Cochrane review of early psychological interventions 
(Hoskins et al., in press). Following on from this previous 
search, we undertook a systematic computerized litera-
ture search of the Cochrane Common Mental Disorders 
Group clinical trials registers databases for studies pub-
lished from January 2008 to May 2016 using the search 
terms PTSD or posttrauma* or post-trauma* or ‘post 
trauma*’ or ‘combat disorder*’ or ‘stress disorder*’. 
These databases are collated and updated on a weekly 
basis from MEDLINE, EMBASE and PsycINFO. 
A further search was undertaken in May 2018. Studies 
were additionally sought from the inclusion/exclusion 
list from a previous systematic review of pharmacother-
apy (Bahji et al., 2019).
Searches were undertaken as part of a search pro-
cess to support development of new PTSD treatment 
guidelines for the International Society for Traumatic 
Stress Studies (ISTSS). We checked the reference lists 
of studies identified in the search, related review 
articles and management guidelines. We contacted 
authors of unpublished studies that had completed 
recruitment where there was a registered protocol on 
a trial register, such as Clinical Trials. We posted 
a list of identified studies on the website of the 
International Society for Traumatic Stress website 
and asked the membership to identify studies that 
we might have missed.
2.5. Study selection
The lead author received the Cochrane database pharma-
cological search hits in an EndNoteX4 file. Studies iden-
tified from our previous review were added and 
duplicates were removed. A small team of secondary 
reviewers were allocated segments of the search hits 
and, alongside the lead author, independently screened 
the titles, and then abstracts. Studies that were clearly 
irrelevant were excluded and potentially relevant ones 
were assessed for inclusion as full texts. The full texts of 
included studies were read and then sorted into 
five categories; monotherapy; augmentation; pharmaco-
logical-assisted therapy; pharmacotherapy versus 
pharmacotherapy; pharmacotherapy versus psychother-
apy. Any discrepancies between reviewers’ decisions were 
resolved by discussion with a third reviewer.
2.6. Data extraction and risk of bias assessment
All data from newly identified studies were double 
extracted by the lead author and a second indepen-
dent reviewer (co-authors) into a standard table and 
any discrepancies were discussed with a third 
reviewer. Data for change from baseline to endpoint 
were extracted where possible, otherwise endpoint 
data were used. Continuous data were extracted for 
clinician-administered PTSD symptom severity using 
the Clinician Administered PTSD Scale as the gold 
standard; for self-rated PTSD, the Davidson Trauma 
Scale was used as the gold standard. If these scales 
were not used, data from alternative scales were 
extracted.
The lead author entered the outcome data in 
Review Manager 5 software, which was then checked 
by an independent second reviewer.
2.7. Risk of bias
The lead author and a small team of independent second 
reviewers assessed the risk of bias for each study, using 
the domain-based evaluation method recommended by 
the Cochrane Collaboration (Higgins & Green, 2011). 
This method considers the following domains: adequate 
random sequence generation; allocation concealment; 
blinding of participants and personnel; blinding of out-
come assessors; incomplete outcome reporting; selective 
reporting; and any other sources of bias. Any discrepan-
cies between the reviewers’ decisions were discussed with 
a third reviewer.
3. Statistical analysis
Review Manager 5 was used to synthesise data using 
meta-analysis and to provide forest plots for contin-
uous data. Confidence intervals were set at 95% for 
all analyses and standard mean differences were used 
(SMD). The degree of heterogeneity was calculated 
using the I2 statistic, and where this was less than 
30%, a fixed effects model was used; otherwise where 
I2 was over 30% a random effects model was used. 
Data were analysed from the intention to treat (ITT) 
sample, where possible, to avoid the effects of bias 
from completers-only analyses. A number of studies 
used a modified intention to treat (mITT) method, 
where participants were analysed, provided they had 
been randomised and received at least one post- 
baseline assessment (sometimes before or after the 
first dose of a study medication or placebo). Whilst 
this does not adhere to the ITT principle of ‘once 
randomised, always analysed’, because of the number 
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of studies that employed this method it was neces-
sary to allow it in order to conduct a meaningful 
review.
3.1. Results
The initial search yielded 10,317 records, with an addi-
tional 51 identified from our previous review. A total of 
19 duplicates were removed, leaving 10,349 titles that 
were screened. 460 full abstracts were reviewed, with 
306 excluded as irrelevant. This then left 154 full-text 
articles which were read and 39 were removed as not 
meeting the inclusion criteria. A total of 115 studies 
were included for our series of pharmacological reviews, 
with 21 studies (Buhmann, Nordentoft, Ekstroem, 
Carlsson, & Mortensen, 2016; De Kleine, Hendriks, 
Kusters, Broekman, & van Minnen, 2012; Difede et al., 
2014; Flanagan, Sippel, Wahlquist, Moran-Santa Maria, 
& Back, 2018; Hien et al., 2015; Litz et al., 2012; 
Mithoefer et al., 2018; Mithoefer, Wagner, Mithoefer, 
Jerome, & Doblin, 2011; Mithoefer et al., 2013; Oehen, 
Traber, Widmer, & Schnyder, 2013; Ot’alora et al., 2018; 
Otto et al., 2003; Popiel, Zawadzki, Pragłowska, & 
Teichman, 2015; Rothbaum et al., 2006, 2014; 
Schneier et al., 2012; Simon et al., 2008; Sonne, 
Carlsson, Bech, Elklit, & Mortensen, 2016; Tuerk 
et al., 2018; Yehuda et al., 2015; Young et al., 2017; 
Zoellner, Telch, Foa, Farach, & McLean, 2017) included 
for this systematic review of pharmacotherapy-assisted 
psychotherapy approaches (Figure 1).
3.2. Description of studies
The characteristics of the included 21 studies are 
detailed in Table 1. Eight studies (Buhmann et al., 
2016; Hien et al., 2015; Otto et al., 2003; Popiel et al., 
2015; Rothbaum et al., 2006; Simon et al., 2008; 
Sonne et al., 2016) assessed the use of an SSRI or 
SNRI in combination with a therapeutic approach. Of 
those eight studies, six (Buhmann et al., 2016; Hien 
et al., 2015; Popiel et al., 2015; Simon et al., 2008; 
Sonne et al., 2016) compared an SSRI/SNRI plus 
therapy approach to therapy plus placebo, with the 
remaining two employing an SSRI comparator (Otto 
et al., 2003; Rothbaum et al., 2006). Four studies 
assessed the use of DCS prior to exposure therapy 
(De Kleine et al., 2012; Difede et al., 2014; Litz et al., 
2012; Rothbaum et al., 2014). Four studies assessed 
the use of MDMA-assisted psychotherapy (Mithoefer 
et al., 2018, 2011; Oehen et al., 2013; Ot’alora et al., 
2018). Four single studies assessed the use of 
a therapeutic intervention assisted by propranolol 
(Brunet et al., 2014), yohimbine (Tuerk et al., 2018), 
cortisol (Yehuda et al., 2015) and methylene blue 
(Zoellner et al., 2017).
The average duration of the trials was 11.7 (±5.1) 
weeks, with an average age of 41.2 (±5.5) years and an 
average sample size of 72 (±74.8) participants. 
Thirteen of the studies took place in the USA, with 
two in Denmark, and single studies in Canada, the 
Netherlands, Poland and Switzerland.
Combat trauma was the predominant trauma type 
in six of the studies, with sexual assault and child-
hood sexual abuse being the predominant trauma 
type in three studies each. Physical assault and refu-
gee/asylum seeker-related trauma were the predomi-
nant trauma type in two studies each, leaving three 
single studies where participants had experienced 
motor vehicle accidents, terrorist attacks and war 
crimes.
3.3. Risk of bias assessments
Risk of bias assessments is included in Table 1. The 
overall quality of included studies was higher than 
those included in our monotherapy and augmenta-
tion reviews, and may be related to the recency of 
publication of those included here. Eleven studies 
Figure 1. Flow diagram of included studies.
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adequately described their method of randomisation 
and allocation concealment. Blinding of participants 
and personnel was deemed to be of low risk of bias in 
11 studies, and blinding of outcome assessors in 16 
studies. Incomplete outcome data were addressed 
adequately in 11 studies. All pre-specified outcome 
variables were adequately reported in three studies, 
where protocols were available.
3.4. Efficacy of pharmacotherapy-assisted 
psychotherapy
Data from four studies (De Kleine et al., 2012; Oehen et al., 
2013; Popiel et al., 2015; Rothbaum et al., 2014) (n = 267) 
were available for inclusion in a meta-analysis of reduction 
in PTSD symptoms for an SSRI plus therapy versus pla-
cebo plus therapy (Figure 2). Three studies used prolonged 
exposure and one used Safety Seeking. The standard mean 
difference was −0.22 (95% CI −0.58 to 0.14) and I2 = 38%.
Four studies (Brunet et al., 2014; Difede et al., 
2014; Ot’alora et al., 2018; Review Manager 
[RevMan], 2014), (n = 224) were available for inclu-
sion in a meta-analysis of reduction in PTSD symp-
toms for DCS-assisted exposure therapy versus 
placebo-assisted exposure therapy (Figure 3). The 
standard mean difference was 0.00 (95% CI −0.45 to 
0.46) and I2 = 59%.
Four studies (Flanagan et al., 2018; Hien et al., 2015; 
Litz et al., 2012; Mithoefer et al., 2011) (n = 85) were 
available for inclusion in a meta-analysis of reduction in 
PTSD symptoms for MDMA-assisted therapy versus 
placebo/MDMA active placebo-assisted therapy 
(Figure 4). The standard mean difference was −1.09 
(95% CI −1.60 to −0.58) and I2 = 0%.
Two studies (Mithoefer et al., 2018; Otto et al., 2003) 
(n = 75) were available for inclusion in a meta-analysis of 
reduction in PTSD symptoms for an SSRI plus therapy 
versus an SSRI alone (Figure 5). The standard mean dif-
ference was 0.2 (95% CI −1.01 to 1.04) and I2 = 58%.
4. Discussion
Only MDMA-assisted therapy was superior to pla-
cebo/active placebo-assisted therapy on reducing 
clinician-rated PTSD symptom severity. There was 
no evidence found to suggest that any of the other 
agents were superior to placebo/active placebo- 
assisted therapy on reducing clinician-rated PTSD 
symptom severity although a very small positive 
effect was found when all pharmacotherapy-assisted 
psychotherapies were considered together.
Several studies examined the efficacy of combining 
evidence based psychological therapies and medica-
tions. The absence of evidence to support the use of 
Figure 2. SSRI-assisted therapy versus placebo-assisted therapy.
Ss = safety seeking therapy, PLC = placebo, PE = prolonged exposure. 
Figure 3. DCS-assisted therapy versus placebo-assisted therapy.
DCS = d-cycloserine, PE = prolonged exposure, VRE = virtual reality exposure, PLB = placebo 
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SSRI or SNRI medication in addition to psychother-
apy was based upon a small number of RCTs with 
mixed methodologies and results. Evidenced based 
medications such as specific SSRIs sertraline, parox-
etine, fluoxetine and the SNRI venlafaxine share in 
common a therapeutic lag in both clinical trials and 
clinical practice. Typically, patients are told to wait 
6–8 weeks after initiation and then after each dose 
escalation before the full clinical effect might be felt. 
Across the included several studies below, there was 
a difference in approach to combining medication 
and therapy; some started both simultaneously, some 
started therapy for several weeks first, then rando-
mised non-responders to continue therapy or add in 
a medication or placebo, and some started medica-
tion in an open-label fashion before randomising and 
adding in therapy. There is an intuitive mechanism 
of action, whereby the small positive effect of medi-
cation when used as monotherapy, may allow parti-
cipants to begin therapy with a smaller symptom 
load and perhaps tolerate and engage in therapy 
more effectively. In those studies that started medi-
cation and therapy simultaneously, or started medi-
cation after open-label therapy, this mechanism may 
not have been allowed time to work effectively.
Buhman et al. (2018) used a pragmatic study design 
in an asylum seeker population (n = 280) of mixed 
traumas to investigate four parallel arms; receiving ser-
traline with or without mianserin augmentation; receiv-
ing sertraline with or without mianserin augmentation 
plus therapy; therapy alone; and waitlist control. There 
was no significant difference found between each 
group, and of note, only 25% of participants who 
received a form of therapy actually received a trauma- 
focussed therapy. Additionally, 27% of participants in 
the therapy only group also received concomitant psy-
chotropic medication.
Hien et al. (2015) compared two groups of partici-
pants with PTSD with alcohol use disorder, who received 
either sertraline plus 12 weeks of Safety Seeking (SS) 
therapy (n = 32), or placebo plus SS (n = 37). There 
were significant improvements in PTSD symptom sever-
ity in the sertraline plus therapy group compared to the 
placebo plus SS group. Interestingly, medication was 
titrated over two weeks prior to therapy commencing, 
a window that is well within the expected therapeutic lag 
of 6–8 weeks. Further research to explore this combina-
tion of sertraline plus SS is warranted, and researchers 
may wish to consider allowing for more time to establish 
participants on a therapeutic dose prior to commencing 
therapy, as their clinical gains might theoretically 
improve.
Popiel et al. (2015) compared three groups of PTSD 
participants with motor-vehicle accident-related 
trauma, receiving either 12 weeks of prolonged expo-
sure (PE) (n = 114), paroxetine (n = 57), or PE plus 
paroxetine (n = 57). There were significant improve-
ments in PTSD symptom severity across all three 
groups, with higher rates of remission in the PE alone 
Figure 5. SSRI plus PE versus SSRI
CBT = cognitive-behavioural therapy, PE = prolonged exposure 
Figure 4. MDMA-assisted therapy versus placebo/active placebo-assisted therapy.
MDMA-AP = MDMA-assisted therapy, PLB = placebo 
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group than in the paroxetine alone group. There was 
again a rapid dose titration in those participants receiv-
ing paroxetine, with maximum doses achieved after 
three to seven days; it could be reasoned that the ther-
apeutic lag may not have clinically synchronised with 
the start of PE in the combined PE plus paroxetine 
group.
Otto et al. (2003) compared two groups of phar-
macotherapy refractory female survivors of the Pol 
Pot regime Cambodia who received either sertraline 
plus five sessions of group cognitive-behavioural 
therapy (CBT) (n = 5), or CBT alone (n = 5). The 
authors reported that the combined group was super-
ior to medication alone, but unfortunately, this small 
drug company-sponsored study was poorly designed 
with high rates of bias and incomplete outcome 
reporting.
Rothbaum et al. (2006) compared a population of 
PTSD participants with predominantly sexual 
assault traumas across two groups; sertraline treat-
ment plus 10 sessions of twice weekly PE (n = 34) 
versus sertraline alone (n = 31). The study design 
allowed for 10 weeks of open-label sertraline prior to 
randomisation, which is commendable in that this 
will allow for any therapeutic lag effect to be negated 
prior to augmentation with therapy. Whilst there 
was no significant difference in PTSD symptom 
severity between these two groups, the combined 
sertraline plus PE group was superior to sertraline 
alone for weaker medication responders in a post- 
hoc analysis.
Schneier et al. (2012) investigated survivors of the 
World Trade Centre attack across two groups; par-
oxetine plus 10 weekly sessions of PE (n = 19) versus 
placebo plus 10 weekly sessions of PE (n = 18). There 
was greater reduction in PTSD symptom severity and 
higher rates of remission in the combined paroxetine 
and PE group at the immediate post-treatment point, 
but these differences were not maintained at follow 
up. The dose of paroxetine was started at 12.5 mg and 
increased in 12.5 mg increments per day for the first 
two weeks, then in 25 mg increments in week three 
and up to a maximum of 50 mg. Again, the simulta-
neous administration of paroxetine and PE without 
allowing for therapeutic lag may negatively affect the 
maximum theoretical benefit from combining 
approaches.
Simon et al. (2008) compared two groups of pre-
dominantly physical and sexual abuse survivors who 
received either paroxetine plus 10 sessions of PE 
(n = 9) or placebo plus PE (n = 14). All participants 
first received eight sessions of PE and non-responders 
were then randomised to either treatment arms. 
There was no significant difference between the 
groups, but there was a small trend towards greater 
reduction of PTSD symptom severity in the placebo 
group.
D-cycloserine (DCS) is a partial NMDA receptor 
agonist, and was investigated in four studies included 
for meta-analysis; the absence of evidence for the use 
of DCS to augment exposure-based therapies is, per-
haps, more surprising as DCS, a partial NMDA 
receptor antagonist, has been found to facilitate fear 
extinction in animal models. There were mixed 
results across the four included studies and DCS 
was given at two different doses and at two different 
time points across the studies; either 50 mg or 
100 mg, and given either 30 minutes or 90 minutes 
prior to therapy.
de Kleine et al. (2012) randomised 67 mostly 
female PTSD participants with sexual abuse as the 
predominant trauma type to two groups; 50 mg DCS 
given orally 1 hour prior to 10 weekly PE sessions 
(n = 33) versus placebo given in the same manner 
plus PE. Concomitant psychotropics were allowed, 
and DCS was only administered for face to face PE 
sessions rather than given as a take-home medication 
to bs used prior to any homework. There were no 
significant differences between the two groups, but in 
a post hoc analysis, there was greater PTSD symptom 
reduction in those participants with higher pre- 
treatment PTSD scores.
Difede et al. (2014) investigated 25 survivors of the 
World Trade Centre attacks across two groups; those 
receiving 100 mg DCS 90 minutes prior to sessions 
2–11 of 12 weekly sessions of CBT, using virtual 
reality exposure (VRE) (n = 13), versus placebo 
given in place of DCS plus the same treatment mod-
ality (n = 12). Pharmacotherapy was allowed across 
both groups, if already on a stable dose of 2 months. 
There were significantly greater remission rates in the 
DCS plus VRE group.
Litz et al. (2012) investigated 26 male combat 
veterans across two groups; those receiving 50 mg 
of DCS given 30 minutes prior to sessions 2–5 of 6 
weekly sessions of exposure, versus those receiving 
placebo given with an identical treatment modality. 
Interestingly, there was significantly less symptom 
reduction in the DCS plus exposure group compared 
to the placebo plus exposure group.
Finally, Rothbaum et al. (2014) randomised 106 
mostly male combat veterans to three groups; group 
1 received 6 weekly sessions of VRE with 50 mg DCS 
given 30 minutes prior to each session (n = 53); 
group 2 received alprazolam plus VRE (n = 50); and 
group 3 received placebo plus VRE (n = 53). Fifty-six 
percent of participants were on a stable dose of psy-
chotropic medications. There were significant 
improvements in PTSD symptom severity across all 
VRE groups, but no significant difference between 
them.
Four single studies assessed the use of propranolol, 
yohimbine, cortisol and methylene blue and as such, 
it was not possible to combine the disparate agents 
EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY 13
into any meaningful meta-analysis. Brunet et al. 
(2018) compared brief, weekly trauma reactivation 
written narrative work using placebo or short and 
long-acting propranolol, which showed significant 
improvements in PTSD symptom severity in the pro-
pranolol group compared to placebo. This approach 
will require further research replication.
Tuerk et al. (2018) compared yohimbine and pla-
cebo when given 1 hour prior to prolonged exposure 
settings over 15 weeks, but found no significant dif-
ference between the comparison arms. Yehuda et al. 
(2015) compared 10 sessions of manualised pro-
longed exposure with either 30 mg cortisol or placebo 
administered 20 minutes prior to sessions 3–10, and 
found veterans administered cortisol were more likely 
to respond to treatment, but there were no significant 
differences between those who had placebo on PTSD 
symptom outcomes.
The positive finding for MDMA-assisted psy-
chotherapy supports the FDA’s decision to grant it 
breakthrough therapy status in 2018 and can potentially 
be explained by its unique psychopharmacological pro-
file. MDMA ingestion is typically characterized by 
2–6 hours of subjective feelings of well-being, sociabil-
ity, and positive mood. It exerts its effect mainly 
through both an increased release and reuptake inhibi-
tion of presynaptic serotonin, and to a lesser effect, 
dopamine. MDMA is also associated with a robust 
release of the neuropeptide oxytocin which precipitates 
pro-social subjective experiences in healthy controls. 
MDMA stimulates release of cortisol and noradrena-
line, which may enhance both emotional engagement 
and extinction learning (Yehuda et al., 2015). Given its 
potential to reduce fear responding, enhance fear 
extinction, and increase prosocial emotional states, 
MDMA has been proposed as a candidate for assisting 
psychological therapies in traumatized people. MDMA 
is currently an illegal drug in all countries of the world 
and its research is tightly controlled.
A novel MDMA-Assisted Psychotherapy (MDMA- 
AP) approach was developed and manualized by the 
non-profit Multidisciplinary Association for Psychedelic 
Studies (MAPS) which includes a female-male therapist 
dyad, weekly 90-min preparation and integration ses-
sions and 2–3 eight-hour-long drug-assisted sessions. 
During the drug-assisted sessions the participants are 
encouraged to focus their attention inwards in 
a comfortable setting, making use of eye shades and ear-
phones with music.
The effects of MDMA-AP have been evaluated in four 
published RCTs of patients with chronic PTSD and our 
meta-analysis of MDMA-AP demonstrated an impress-
ive effect size for this emerging intervention. Two of the 
included studies also included participants who were 
treatment-resistant, which was defined in one study as 
having previously undergone at least 6 months of therapy 
or 3 months of SSRI treatment. Notably, one long-term 
follow up study (Zoellner et al., 2017) found that clinical 
gains were largely sustained over time, with no evidence 
of addiction or abuse of MDMA over time and a positive 
adverse effect profile.
It is, however, difficult to have ultimate confidence 
in the effect size found because of the small numbers 
of participants in published studies (n = 85), as well 
as several methodological and other issues. A key 
difficulty in this research is the ability to maintain 
the blind, as MDMA demonstrates acute effects likely 
noticeable compared to placebo. However, all but one 
(Hien et al., 2015) of the four MDMA studies utilised 
a low-dose MDMA active placebo to assist in main-
taining the blind.
MDMA-AP uses a non-evidence-based psy-
chotherapy model, which, to our knowledge, has not 
been evaluated against other TFPTs in a medication- 
free setting. Lastly, all four published studies have 
been funded and managed by a single sponsor 
(MAPS), which potentially increases the risk of biased 
results. There are currently several ongoing Phase 2 
studies in the USA, Israel and Canada, with more 
open-label feasibility studies planned across nearly 
a dozen EU sites. In the USA, the regulatory body 
(Food and Drug Administration) has granted 
Breakthrough Therapy Designation for MDMA-AP, 
with Phase 3 studies planned in the coming years. 
Future research will benefit from follow-up studies 
replicating and extending this work in additional 
research groups.
4.1. Study limitations
This study set out to examine the effects of drug-assisted 
therapies, and delineated approaches into three groups; 
conventional pharmacotherapy plus therapy, MDMA- 
AP and DCS-AP. A major strength of the study was 
adherence to the robust and state of the art systematic 
review and meta-analysis methodology advocated by The 
Cochrane Collaboration. There were, however, relatively 
few studies with small numbers per group with which to 
perform meta-analyses in each group, raising power and 
other issues with respect to the results. As the field pro-
gresses, future studies should broaden our knowledge 
and allow more confidence in the results of meta- 
analyses. Unfortunately, a significant proportion of stu-
dies conducted their analyses on a modified intention to 
treat (mITT) population, which does not adhere to the 
‘once randomised, always analysed’ principle of an inten-
tion to treat analysis and therefore may bias the outcome. 
However, due to the number of studies which employed 
mITT analyses, we chose to include them in order to be 
able to conduct a meaningful review.
In the conventional SSRI/SNRI pharmacotherapy 
plus therapy group, in addition to the small number 
of studies, there was a wide variation in methodology 
and overall quality. Many of the included studies 
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initiated an SSRI or SNRI followed by therapy after as 
little as two weeks and many did not report 
a measure of response to medication prior to therapy. 
This approach has several problems; it is unlikely to 
allow participants to feel the most benefit from the 
medication prior to therapy and it does not allow 
reviewers to understand differences between medica-
tion responders and non-responders who then go on 
to receive therapy. An alternative and preferable 
approach in future research would be to augment 
an established pharmacological treatment with psy-
chotherapy. Further research in this area is, therefore, 
warranted, not least because combining conventional 
medications with TFPT is very common in clinical 
practice.
In the DCS-AP group, DCS was given at various 
doses and intervals prior to therapy, which was also 
given for a wide durational range (6–12 weeks). DCS 
was only given before formal therapy sessions; the 
therapists and authors did not adequately explore the 
possibility of giving ‘take home’ doses of DCS for use 
in completing homework between sessions. DCS-AP 
was given to participants who were not identified as 
treatment-resistant or severe, in comparison to 
MDMA-AP, begging the question who would DCS- 
AP be suitable for. Additionally, concomitant psycho-
tropics were allowed in the majority of DCS studies, 
further confounding the true efficacy of this drug.
In the MDMA-AP studies, the very novel subjective 
experience of the drug is difficult to completely blind, but 
the use of active low-dose placebo seems to have been 
effective and should be employed in future research.
The benefit of all studies being funded and man-
aged by a single sponsor (in terms of consistency, 
personnel training and high quality of reporting) is 
potentially offset by the risk of bias we associated 
with authors who are affiliated with one of the inter-
ventions. However, given the difficulties inherent in 
funding research into an experimental drug that is 
tightly regulated across the globe, very few groups are 
in a position to conduct research on MDMA.
4.2. Implications
Overall, there are no immediate clinical implications 
resulting from this study. MDMA-AP is the most pro-
mising novel treatment for chronic and often treatment- 
resistant PTSD, but cannot be recommended as a clinical 
treatment yet; larger scale Phase 3 studies are required to 
determine whether this is a safe and effective approach 
that can be recommended.
Combination approaches using SSRIs and SNRIs 
with exposure therapies are a common clinical prac-
tice, but are not currently supported by a sparse 
literature that addresses them; further research of 
conventional agents, which are initiated and titrated 
up to the highest tolerable dose prior to initiated 
therapy (pharmacological therapy augmented by psy-
chotherapy), is clearly needed and of great clinical 
interest. Likewise, further research of DCS-assisted 
exposure therapy is required to assess whether higher 
doses given at a longer duration prior to therapy 
sessions would be superior to placebo.
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